Verona Pharma plc (VRNA)

Market Cap	5.33B
Revenue (ttm)	42.28M
Net Income (ttm)	-173.42M
Shares Out	84.98M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	857,196
Open	64.22
Previous Close	64.51
Day's Range	62.00 - 64.50
52-Week Range	11.39 - 70.40
Beta	0.39
Analysts	Strong Buy
Price Target	66.83 (+6.59%)
Earnings Date	May 8, 2025

About VRNA

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 27, 2017
• Employees: 209
• Stock Exchange: NASDAQ
• Ticker Symbol: VRNA
• Website: https://www.veronapharma.com

Analyst Forecast

According to 6 analysts, the average rating for VRNA stock is "Strong Buy." The 12-month stock price forecast is $66.83, which is an increase of 6.59% from the latest price.

Price Target

$66.83

(6.59% upside)

Analyst Consensus: Strong Buy